Gamma2A Jak2 Cell Line
Invented by George Stark at Cancer Research UK London Research Institute: Lincoln's Inn Fields Cleveland Clinic Foundation
2C4-Gamma2A cell line
Invented by George Stark , Ian Kerr
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
- Datasheet
- References (4)
- Inventor Info
Info
| Catalogue Number | 154234 |
| Antigen/Gene or Protein Targets | Interferon gamma; JAK2 |
| Parental Line | 2C4 cell line (a derivative of HT 1080 cell line) |
| Host | Human |
| Disease Keywords | Fibrosarcoma |
| Model | Mutant |
| Relevance | Mutant gamma2A cells retain a wild-type interferon (IFN)-alpha/beta response (e.g., class I HLA Binding of IFN-gamma to gamma2A cells is normal), but the cells lack detectable JAK2 mRNA and protein and are completely defective in all aspects of the IFN-gamma response. More specifically, they are defective in IFN-gamma inducible activation of the JAK/STAT pathway, gene expression, and an antiviral state with respect to encephalomyocarditis (EMC) virus. In all cases, JAK2 (but not JAK1 or Tyk2 restores a wild-type phenotype. The gamma2A mutant cells lack inducible phosphorylation of the IFN-gamma receptor 1 (R1) subunit, JAK1, and STAT1 and IFN-gamma-inducible cell surface expression of class I and II HLAs. In each case, the wild-type IFN-gamma response is restored in gamma2A/JAK2 transfectants (Kohlhuber et al., 1997). |
| Production Details | The 2C4-gamma2A cell line is a derivative of the 2C4 cell line which is a clonal derivative of the human fibrosarcoma cell line HT 1080. The 2C4 cell line clone expresses the simple cell-surface marker CD2 (normally expressed only on T cells) under the control of the 9-27 gene promoter. The 9-27 gene promoter is inducible by interferon gamma; fluorescence-activated cell sorter (FACS) analysis was used to screen cells for loss or gain of interferon gamma inducibility of CD2 expression. Cell line 2C4-gamma2A was isolated by mutagenesis of 2C4 and rounds of sorting showing interferon gamma responsiveness (interferon gamma induction of CD2 expression) had been lost in comparison to wild-type 2C4 cells (Watling et al., 1993). |
| Research Area | Cell Signaling & Signal Transduction, Gene Expression, Immunology, Virology |
| Recommended Growing Conditions | DMEM + 10% heat-inactivated FBS + 400ug G418 per ml |
| Positive Control | 2C4 cell line |
2C4 cell line
Invented by George Stark at Cleveland Clinic Foundation Cancer Research UK London Research Institute: Lincoln's Inn Fields
References: 4 entries
Kohlhuber et al. 1997. Mol Cell Biol. 17(2):695-706. PMID: 9001223.
A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.
Europe PMC ID: 9001223
Watling et al. 1993. Nature. 366(6451):166-70. PMID: 7901766.
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.
Europe PMC ID: 7901766
Add a reference
References: 4 entries
Kohlhuber et al. 1997. Mol Cell Biol. 17(2):695-706. PMID: 9001223.
A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.
Watling et al. 1993. Nature. 366(6451):166-70. PMID: 7901766.
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.
Add a reference
Inventor Information
Inventors
|
George Stark |
|
|
Ian Kerr |
